Please assess the completion status of the following clinical trial:

Trial Title: Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* A signed and dated written informed consent prior to study participation.~* Male or female adults.~A female is eligible to enter and participate in this study if she is of:~non-childbearing potential (i.e., physiologically incapable of becoming pregnant), including any female who is post-menopausal; or child-bearing potential, has a negative pregnancy test at Visit 1/Visit 1A, and agrees to one of the protocol-specified acceptable contraceptive methods used consistently and correctly (i.e. according to the approved product label and the instructions of the physician for the duration of the study - Screening through follow-up contact)~* 40 to 80 years of age at Visit 1~* An established clinical history of COPD~* Current or previous cigarette smokers with a history of cigarette smoking of ≥ 10 pack-years 1.~* A post-albuterol/salbutamol FEV1/FVC ratio of ≤0.70 and a post-albuterol/salbutamol FEV1 of ≥35 and ≤70% of predicted normal values~Exclusion Criteria:~Subjects meeting any of the following criteria must not be enrolled in the study:~* Women who are pregnant or lactating.~* A current diagnosis of asthma.~* Known respiratory disorders other than COPD including but not limited to α-1 antitrypsin deficiency as the underlying cause of COPD, active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, and interstitial lung disease.~* Any previous lung resection surgery (e.g., lung volume reduction surgery or lobectomy)~* Clinically significant Chest X-ray or computed tomography (CT) scan abnormalities within 6 months prior to Visit 1 that are not believed to be due to COPD.~* Use of oral corticosteroids or antibiotics for COPD within 6 weeks prior to Visit 1.~* Hospitalization for COPD or pneumonia within 3 months prior to Visit 1.~* Use of antibiotics for a lower respiratory tract infection within 30 days prior to Visit 1.~* Clinically significant and uncontrolled cardiovascular, neurological, psychiatric, renal, gastro-intestinal, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities.~* An abnormal and clinically significant 12-lead electrocardiogram (ECG) that results in active medical problem.~* Positive for Hepatitis B or Hepatitis C at Visit 1.~* A current malignancy or previous history of cancer in remission for \<5 years prior to Visit 1~* A history of allergy or hypersensitivity to ipratropium, tiotropium, or atropine and any of their derivatives, lactose/milk protein or magnesium stearate.~* Medical diagnosis of narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that in the opinion of the study investigator would prevent use of an inhaled anticholingeric.~* Medically unable to withhold albuterol/salbutamol for 6 hours prior to spirometry testing at each study visit or to withhold ipratropium (if applicable) for the 6-hour period prior to the first 3 study visits (ipratropium cannot be used after Visit 3).~* Additional Medications: Unable to stop using certain medications such as bronchodilators and corticosteroids for the protocol-specified times prior to Visit 1 (the Investigator will discuss the specific medications)~* Use of inhaled corticosteroids at a dose greater than 1000 mcg/day of fluticasone propionate or equivalent within 30 days prior to Visit 1.~* Use of long-term oxygen therapy (LTOT) or supplemental oxygen required for greater than 12 hours a day. Oxygen use as needed is not exclusionary.~* Clinically significant sleep apnea that requires continuous positive airway pressure (CPAP)~* Use of regular nebulized therapy~* Use of nocturnal positive pressure or non-invasive positive pressure ventilation (NIPPV)~* Participation in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Visit 1.~* An investigator, sub-investigator, study coordinator, employee of a participating investigator or study site, or immediate family member of the above who is involved in this study~* History of psychiatric disease, intellectual deficiency, poor motivation, substance abuse in the two years prior to Visit 1 (including drug and alcohol), or other conditions, which will limit the validity of informed consent to participate in the study.~* Use of GSK233705B in previous studies.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): GSK233705 12.5mcg
- Arm 2 (Type: EXPERIMENTAL): GSK233705 25mcg
- Arm 3 (Type: EXPERIMENTAL): GSK233705 50mcg
- Arm 4 (Type: EXPERIMENTAL): GSK233705 100mcg
- Arm 5 (Type: EXPERIMENTAL): GSK233705 200mcg
- Arm 6 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete